[1] Schaffler MB, Kennedy OD. Osteocyte signaling in bone. Curr Osteoporos Rep. 2012;10(2):118-125.
[2] Kular J, Tickner J, Chim SM, et al. An overview of the regulation of bone remodelling at the cellular level. Clin Biochem. 2012;45(12):863-873.
[3] Lippuner K.The future of osteoporosis treatment - a research update. Swiss Med Wkly. 2012;142:w13624.
[4] McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126(1):13-20.
[5] Rizzoli R, Reginster JY. Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol. 2011;4(5):593-604.
[6] Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med. 2009;60:85-96.
[7] Bagan J, Scully C, Sabater V, et al. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncol. 2009;45(7):551-554.
[8] Kikuiri T, Kim I, Yamaza T, et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res. 2010;25(7):1668-1679.
[9] Esbrit P, Alcaraz MJ. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Biochem Pharmacol. 2013;85(10): 1417-1423.
[10] Morley P, Whitfield JF, Willick GE. Parathyroid hormone: an anabolic treatment for osteoporosis. Curr Pharm Des. 2001; 7(8):671-687.
[11] Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13): 1207-1215.
[12] Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349(13):1216-1226.
[13] Lombardi G, Di Somma C, Rubino M, et al. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics. J Endocrinol Invest. 2011;34(7 Suppl):18-22.
[14] Drake MT, Srinivasan B, Mödder UI, et al. Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. Bone. 2011;49(3):349-355.
[15] Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92(8): 3001-3005.
[16] Komrakova M, Stuermer EK, Werner C, et al. Effect of human parathyroid hormone hPTH (1-34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. Bone. 2010;47(3):480-492.
[17] Subbiah V, Madsen VS, Raymond AK, et al. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010;21(6):1041-1045.
[18] Mikami Y, Somei M, Takagi M. A tryptamine derivative, SST-VEDI-1, inhibits apoptosis and stimulates mineralization in osteoblasts. Endocr J. 2009;56(5):665-678.
[19] Mikami Y, Somei M, Tsuda H. SSH-BM-I, a tryptamine derivative, stimulates mineralization in terminal osteoblast differentiation but inhibits osteogenesis of pre-committed progenitor cells. J Pharmacol Sci. 2011;116(1):63-72.
[20] Somei M. Definitions of IPF and APF. Heterocycles. 2004; 64(1):483.
[21] Somei M, Iwaki T, Yamada F, et al.The ideal synthetic method aimed at the leads for an a2-BLOCKR, an inhibitor of blood platelet aggregation, and an anti-osteoporosis agent. Heterocycles. 2006;68(1):1565-1569.
[22] Mikami Y, Senoo M, Lee M, et al. Inhibitory effects of a tryptamine derivative on ultraviolet radiation-induced apoptosis in MC3T3-E1 mouse osteoblasts. J Pharmacol Sci. 2011;115(2):214-220.
[23] Ichioka N, Inaba M, Kushida T, et al. Prevention of senile osteoporosis in SAMP6 mice by intrabone marrow injection of allogeneic bone marrow cells. Stem Cells. 2002;20(6): 542-551.
[24] Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379(9817):713-720.
[25] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.
[26] Moad M, Pal D, Hepburn AC, et al. A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells. Eur Urol. 2013;64(5):753-761.
[27] Vitale AM, Wolvetang E, Mackay-Sim A. Induced pluripotent stem cells: a new technology to study human diseases. Int J Biochem Cell Biol. 2011;43(6):843-846.
[28] Zhang G, Shang B, Yang P, et al. Induced pluripotent stem cell consensus genes: implication for the risk of tumorigenesis and cancers in induced pluripotent stem cell therapy. Stem Cells Dev. 2012;21(6):955-964.
[29] Matsumoto T, Kano K, Kondo D, et al. Mature adipocyte- derived dedifferentiated fat cells exhibit multilineage potential. J Cell Physiol. 2008;215(1):210-222.
[30] Yagi K, Kondo D, Okazaki Y, et al. A novel preadipocyte cell line established from mouse adult mature adipocytes. Biochem Biophys Res Commun. 2004;321(4):967-974.
[31] Oki Y, Watanabe S, Endo T, et al. Mature adipocyte-derived dedifferentiated fat cells can trans-differentiate into osteoblasts in vitro and in vivo only by all-trans retinoic acid. Cell Struct Funct. 2008;33(2):211-222.
[32] Kazama T, Fujie M, Endo T, et al. Mature adipocyte-derived dedifferentiated fat cells can transdifferentiate into skeletal myocytes in vitro. Biochem Biophys Res Commun. 2008; 377(3): 780-785.
[33] Sakuma T, Matsumoto T, Kano K, et al. Mature, adipocyte derived, dedifferentiated fat cells can differentiate into smooth muscle-like cells and contribute to bladder tissue regeneration. J Urol. 2009;182(1):355-365.
[34] Jumabay M, Matsumoto T, Yokoyama S, et al. Dedifferentiated fat cells convert to cardiomyocyte phenotype and repair infarcted cardiac tissue in rats. J Mol Cell Cardiol. 2009;47(5):565-575.
[35] Ohta Y, Takenaga M, Tokura Y, et al. Mature adipocyte-derived cells, dedifferentiated fat cells (DFAT), promoted functional recovery from spinal cord injury-induced motor dysfunction in rats. Cell Transplant. 2008;17(8): 877-886.
[36] Nur R, Fukuda N, Matsumoto T, et al. Implantation of dedifferentiated fat cells ameliorates habu snake venom-induced chronic renal dysfunction in tenascin-C- deficient mice. Nephron Exp Nephrol. 2008;110(3):e91-98.
[37] Gronthos S, Mankani M, Brahim J, et al. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A. 2000;97(25):13625-13630.
[38] Miura M, Gronthos S, Zhao M, et al. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci U S A. 2003;100(10):5807-5812.
[39] Tamaoki N, Takahashi K, Tanaka T, et al. Dental pulp cells for induced pluripotent stem cell banking. J Dent Res. 2010;89(8): 773-778.
|